Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

Five months ago, J&J also revealed its plan to spend $2 billion over the next 10 years to operate a 160,000-square-foot ...

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.

Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indicationsSOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE ...

Strategic acquisition accelerates Title21’s mission to deliver integrated digital solutions for regulated healthcare and life ...

The first half of 2025 has been a notable one for Cellares. The cell therapy manufacturer operates its first commercial-scale Integrated Development and Manufacturing Organization Smart Factory in ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important ...

As it applies to the development of cell therapies, AstraZeneca’s chief of global operations, Pam Cheng, admits that the company is a “little late to join the party.” But just because AZ has trailed ...